On January 31, 2025, Elizabeth Hougen, Executive Vice President, Finance & Chief Financial Officer of Ionis Pharmaceuticals Inc (IONS, Financial), sold 1,523 shares of the company. Following this transaction, the insider now owns 110,500 shares of the company. The details of this transaction can be found in the SEC Filing.
Ionis Pharmaceuticals Inc (IONS) is a biotechnology company that focuses on discovering and developing RNA-targeted therapeutics. The company uses its proprietary antisense technology to develop drugs for a broad range of diseases, including cardiovascular, neurological, and metabolic diseases, as well as cancer.
Over the past year, Elizabeth Hougen has sold a total of 10,393 shares and has not purchased any shares. The insider transaction history for Ionis Pharmaceuticals Inc shows that there have been 1 insider buy and 30 insider sells over the same timeframe.
On the day of the recent sale, shares of Ionis Pharmaceuticals Inc were trading at $32.44, giving the stock a market cap of $5.073 billion. The stock's GF Value was $31.99, resulting in a price-to-GF-Value ratio of 1.01, indicating that the stock is fairly valued based on its GF Value.
The GF Value is an intrinsic value estimate developed by GuruFocus, calculated based on historical multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow that the stock has traded at. It also includes a GuruFocus adjustment factor based on the company’s past returns and growth, as well as future estimates of business performance from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
